Drug Approval | November 21, 2022
Aurobindo Pharma receives 10 observations for Unit IX
The company had responded to the agency and carried out the required corrective actions.
The company had responded to the agency and carried out the required corrective actions.
The product is expected to be launched by Q4 FY23.
The approval further strengthens the Potassium Chloride franchise for the company.
Strand’s new offering will help people better understand and manage diseases through genomic sequencing
Zydus becomes the only Indian oncology player to venture into prognosis and diagnosis along with treatment planning
The company registered with REACH Certificate for Ethyl Acetate with a tonnage band of more than 1000 TPA
The company sees the business reaching $100mn
First PARP inhibitor to demonstrate clinical benefit in radiographic progression-free survival in combination with a new hormonal agent with or without homologous recombination repair gene mutations
Kauliv provides reusable and disposable pen2 device options to cater to the global market demand.
The company has reported total income of Rs. 4.59 crores during the period ended September 30, 2022
Subscribe To Our Newsletter & Stay Updated
